Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Published:2011-06-14 Issue:8 Volume:10 Page:1394-1406
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Bhagwat Shripad V.,Gokhale Prafulla C.,Crew Andrew P.,Cooke Andy,Yao Yan,Mantis Christine,Kahler Jennifer,Workman Jennifer,Bittner Mark,Dudkin Lorina,Epstein David M.,Gibson Neil W.,Wild Robert,Arnold Lee D.,Houghton Peter J.,Pachter Jonathan A.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

2. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study;Clinical Genitourinary Cancer;2024-10

3. Non-Coding RNAs of Mitochondrial Origin: Roles in Cell Division and Implications in Cancer;International Journal of Molecular Sciences;2024-07-08

4. 177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model;Antibodies;2024-06-27

5. Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics;Investigational New Drugs;2024-06-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP